Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827337 | 0.92 | ABL1 (0.58) | ABL1TRPA1MGLLMAPTKMT2A | |
| SCHEMBL2827621 | 0.92 | ABL1 (0.57) | ABL1TRPA1MGLLMAPTKMT2A | |
| SCHEMBL2829180 | 0.89 | MAPT (0.60) | ABL1MGLLMAPTKMT2ANPSR1 | |
| SCHEMBL2830760 | 0.89 | ABL1 (0.56) | ABL1TRPA1MGLLMAPTKMT2A | |
| SCHEMBL2825544 | 0.87 | MAPT (0.64) | MGLLMAPTKMT2ACYP3A4CYP2C9 | |
| SCHEMBL2825667 | 0.86 | SMN1; SMN2 (0.63) | MGLLMAPTKMT2ACYP3A4CYP2C9 | |
| SCHEMBL2826777 | 0.85 | NPSR1 (0.66) | TRPA1MGLLMAPTKMT2ANPSR1 | |
| SCHEMBL2827972 | 0.85 | MAPT (0.59) | TRPA1MGLLMAPTKMT2ANPSR1 | |
| SCHEMBL2827614 | 0.85 | HDAC1 (0.56) | MGLLMAPTKMT2ACYP3A4CYP2C9 | |
| SCHEMBL2829949 | 0.84 | MAPT (0.55) | TRPA1MGLLMAPTKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948650-B1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | ORGANON NV (NL) | 2010-05-26 | — | — | EP | claimed |
| US-20100099722-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES | MSD OSS B.V. (NL) | 2010-04-22 | — | — | US | claimed |
| EP-1948650-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. Organon (NL) | 2008-07-30 | — | — | EP | claimed |
| WO-2007054474-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. ORGANON (NL) | 2007-05-18 | — | — | WO | claimed |
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | AKZO NOBEL N.V. (NL) | 2007-05-10 | — | — | US | claimed |
| EP-1948650-B1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | ORGANON NV (NL) | 2010-05-26 | — | — | EP | disclosed |
| US-20100099722-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES | MSD OSS B.V. (NL) | 2010-04-22 | — | — | US | disclosed |
| EP-1948650-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. Organon (NL) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054474-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. ORGANON (NL) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | AKZO NOBEL N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | TRPV1, TRPV3, TRPV4 | ABL1 2275/4885TRPA1 4/4885MGLL 3317/4885 |
| US-20100099722-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES | TRPV1, TRPV3, TRPA1 | ABL1 2118/4885TRPA1 3/4885MGLL 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.